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Background: (−)-Solenopsin A is a piperidine alkaloid that is a component of the venom of the fire ant Solenopsis
invicta. Previously, we have demonstrated that solenopsin exhibit anti-angiogenic activity and downregulate
phosphoinositol-3 kinase (PI3K) in the p53 deficient renal cell carcinoma cell line 786-O. Solenopsin has structural
similarities to ceramide, a major endogenous regulator of cell signaling and cancer therapy induced apoptosis.
Methods: Different analogs of solenopsin were synthesized in order to explore structure-activity relationships. The
anti-proliferative effect of solenopsin and analogs was tested on six different cell lines, including three tumor cell
lines, two normal cutaneous cell lines, and one immortalized hyperproliferative cell line. FRET-based reporters were
used to study the affect of solenopsin and analogs on Akt activity and PDK1 activation and sucrose density gradient
fractionation was performed to examine recruitment of PTEN to membrane rafts. Western-blotting was used to
evaluate the affect of solenopsin and analogs on the Akt and the MAPK 44/42 pathways in three different tumor
cell lines. Measurement of cellular oxygen consumption rate together with autophagy staining was performed to
study mitochondrial function. Finally, the affect of solenopsin and analogs on ROS production was investigated.
Results: In this paper we demonstrate that solenopsin analogs with potent anti-proliferative effects can be synthesized
from inexpensive dimethylpyridines. To determine whether solenopsin and analogs act as ceramide analogs, we
examined the effect of solenopsin and analogs on two stereotypic sites of ceramide activity, namely at lipid rafts
and mitochondria. We found that native solenopsin, (−)-solenopsin A, inhibits functional Akt activity and PDK1
activation in lipid rafts in a similar fashion as ceramide. Both cis and trans analogs of solenopsin reduce mitochondrial
oxygen consumption, increase reactive oxygen, and kill tumor cells with elevated levels of Akt phosphorylation.
However, only solenopsin induces mitophagy, like ceramide.
Conclusions: The requirements for ceramide induced mitophagy and inhibition of Akt activity and PDK1
activation in lipid rafts are under strict stereochemical control. The naturally occurring (−)-solenopsin A mimic
some of the functions of ceramide and may be therapeutically useful in the treatment of hyperproliferative and
malignant disorders of the skin, even in the presence of elevated levels of Akt.
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(−)-Solenopsin A is a piperidine alkaloid that is a com-
ponent of the venom of the fire ant Solenopsis invicta.
Previously, we demonstrated that solenopsin exhibited
anti-angiogenic activity and downregulated phosphoinositol-
3 kinase (PI3K) in the p53 deficient renal cell carcinoma cell
line 786-O [1]. Solenopsin structurally resembles ceramides
in chemical structure (Figure 1). Ceramides are fatty acid
amides of sphingosine, which play a crucial role in
homeostasis of the skin and other organs [2-5]. Defects
in the production of ceramides may inhibit physiologic
cell death, leading to the persistence of inflammatory
and neoplastic cells [5-7]. Large-scale extraction of
solenopsin from fire ants is not feasible, and current
synthetic routes are multistep routes with low yields.
Thus, we devised a simple two-step synthesis of solenop-
sin analogs starting from inexpensive dimethyl pyridine.
We examined the effect of solenopsin and analogs on two
stereotypic sites of ceramide activity, lipid rafts and mito-
chondria [7,8]. We show that native (−)-solenopsin A has
ceramide-like activity in lipid rafts and mitochondria.
Finally, we show that solenopsin and analogs kill tumor
cells regardless of phosphatase and tensin homolog
(PTEN) status or Akt activation. Given that loss ofFigure 1 Compounds studied in this paper and synthetic procedures for p
the venom of the fire ant solenopsis invicta. (+)-Solenopsin A is the enantio
resembles the structure of ceramides, which are fatty acid amides of sphin
organs. Solenopsin analogs S11-S14 were synthesized by deprotonation o
n-butyllithiium, followed by addition of alkyl bromides. Analog S15 was syn
reagent decylmagnesium bromide. The solenopsin analogs (S11-S15) were sPTEN and elevation of Akt are major mechanisms of
resistance to chemotherapy [9,10], the use of solenopsin




(+)-Solenopsin A and (−)-solenopsin A were synthesized
as HCl salts as previously described [1]. Compound
S11-S14 were synthesized by deprotonation of 2,6-
dimethylpyridine (S12-S14) or 2,4,6-trimethylpyridine
(S11) by n-butyllithium, followed by addition of alkyl
bromides (Figure 1). S15 was synthesized by treating
pyridine-2-carboxaldehyde with the Grignard reagent
decylmagnesium bromide (Figure 1). The solenopsin ana-
logs (S11-S15) were successfully obtained after hydrogen-
ation of the various 2-alkylpyridines (Figure 1). Detailed
synthetic procedures and characterization data can be
found in the Additional file 1.
Cells and culture conditions
In this study eight different cell lines were used: human
A375 melanoma cells, human A2058 melanoma cells,
immortalized murine endothelial SVR cells [11-13],reparation of compounds S11-S15. (−)-Solenopsin A is a component of
mer of the naturally occurring solenopsin. The structure of solenopsin
gosine that play a crucial role in homeostasis of the skin and other
f 2,6-dimethylpyridine (S12-S14) or 2,4,6-trimethylpyridine (S11) by
thesized by treating pyridine-2-carboxaldehyde with the Grignard
uccessfully obtained after hydrogenation of the various 2-alkylpyridines.
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cyts, HaCaTs (immortalized human keratinocytes), murine
embryonic NIH3T3 fibroblast cells, and human UM-
SCC1A squamous carcinoma cells. All cell lines were
grown in DMEM with 10% fetal bovine serum, except
for primary keratinocytes which were grown in serum
free keratinocyte growth media and primary melanocytes
that were grown in complete melanocyte growth media
Proliferation studies
A375, A2058, SVR, primary melanocyte, primary keratino-
cyte, and HaCaT cells were treated with test compounds
for 24 hours, followed by cell counting with a Coulter
Counter. All compounds were tested in quadruplicates.
For A375s, A2058s, SVRs, and primary melanocytes
50,000 cells/well were plated. Due to difficulty growing
the cells, primary keratinocytes and HaCaTs were plated
at a concentration of 20,000 cells/well, and 15,000 cells/
well respectively. All cells were treated with 20 μM of cer-
amide C2. A375s, A2058s, and SVRs were treated with
10 μM of (−)-solenopsin A, (+)-solenopsin A, or analogs
S11-S15, whereas primary melanocytes, primary keratino-
cytes, and HaCaTs were treated with 20 μM of solenopsin
and analogs.
FRET-based reporter construct
The development of the biocensors Lyn-PARE and
AktAR has been described previously [14,15]. Briefly,
AktAR was generated by a fluorescent protein pair, ceru-
lean and cpVE172, sandwiching a forkhead-associated
binding domain (FHA1) and an Akt substrate domain
(FOXO) [15]. Lyn-PARE was generated by sandwiching
full-length PDK1 between a FRET pair, ECFP (cyan
fluorescent protein) and citrine (yellow fluorescent pro-
tein) [16], and a motif generated from the Lyn-kinase
gene was added to the 5’-end to target the construct to
raft microdomains [14].
Cell transfection and imaging
Cell transfection and imaging was conducted as previ-
ously described [14,15]. NIH3T3 cells were treated for
1 h with DMSO solutions of ceramide C2 (50 μM),
(+)-solenopsin A (10 and 20 μM), (−)-solenopsin A (10
and 20 μM), and analogs S11-S15 (10 μM). A more de-
tailed description of the experimental procedure can be
found in the Additional file 1.
Sucrose density gradient fractionation
Cells were treated for 1 h with 20 μM DMSO solutions
of (+)-solenopsin A, (−)-solenopsin A, analogs (S12-
S15), or 50 μM of ceramide. Lipid raft fractionation was
performed with a 5-40% sucrose discontinuous gradient
as previously described [17,18]. After ultracentrifugation,
thirteen 385 μL fractions were collected, starting fromthe top of the tube. Equal volumes of each fraction were
analyzed by Western blot with rabbit polyclonal anti-
bodies for caveolin-1 and PTEN. A more detailed de-
scription of the experimental procedure can be found in
the Additional file 1.
Western blot analysis
Cells were grown in T-25 flasks until 80% confluent
followed by treatment for 24 h with 10 μM DMSO solu-
tions of (+)-solenopsin A, (−)-solenopsin A, or analogs
(S11-S15). Sample aliquots normalized for protein quan-
tities were size fractionated by 10% SDS-PAGE, and the
proteins were transferred to a PVDF membrane. The
blots were incubated in blocking solution; TBS with 5%
(wt/vol) powdered nonfat milk for 1 h at room temperature,
followed by incubation over night with rabbit poly-
clonal p-Akt S473, p-MAPK 44/42, and Β-actin.
Measurement of oxygen consumption rate (OCR)
UM-SCC1A cells were plated 15,000 cells/well in 200 μl
DMEM supplemented with 10% FBS and 1% penicillin-
streptomycin in each well of a 96-well Seahorse plate
and incubated overnight at 37°C with 5% CO2. Cells
were treated with 10 μM of compound or DMSO and
incubated for 24 hours. OCR was measured as pmoles
O2/minute using the Seahorse Biosciences instrument
per manufacturer’s instructions. Protein amounts in each
well were quantified using the Thermo Scientific Pierce
Protein Assay, per manufacturer’s instructions.
Autophagosome staining
UM-SCC1A cells were treated with DMSO (control) or
10 μM of (−)-solenopsin A or analog S14 for 18 h. The
cells were stained using a Cyto-ID Autophagy Staining
assay from Life Technologies.
Measurement of ROS with dihydroethidium (DHE)
Briefly, A375 and SVR cells were treated for 24 h with
10 μM DMSO solutions of (+)-solenopsin A, (−)-sole-
nopsin A, or analogs (S11-S15). Cells were washed, pel-
leted, suspended in 10 μM DHE and incubated for
10 min. Thereafter cells were counted using a Becton
Dickinson FACScan flow cytometer. Mean values of
DHE fluorescence intensity were compared and all sam-
ples were repeated in triplicate. A more detailed descrip-
tion of the experimental procedure can be found in the
Additional file 1.
Determination of cytotoxicity by MTT assay
MTT reagent was added to the tissue inserts after
72 hours treatment with 10 μM of Solenopsin A and an-
alogs S12 and S14 followed by incubation for 3 hours at
37°C with 5% CO2. Thereafter, MTT was extracted from
the tissues and the absorbance was measured at 570 nm.
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by MatTek; viability of less than 50% was determined to
be irritant and cytotoxic. H&E staining of the tissues from
the cultures inserts were also performed; see Additional
file 1 for more detailed experimental procedures.
Results
Structure-activity relationships of solenopsin and analogs
Different analogs of solenopsin were synthesized (Figure 1)
in order to explore structure-activity relationships. Three
different tumor cell lines, relevant for skin, were used to
assess anti-proliferative potency: human A375 melanoma
cells, human A2058 melanoma cells, and murine SVR
angiosarcoma cells. No significant difference between the
naturally occurring compound, (−)-solenopsin A, and its
enantiomer (+)-solenopsin A could be seen in any of the
tumor cell lines (Figure 2). Both of these compounds have
trans geometry. The mixture of the two cis isomers of
solenopsin, S12, show weaker anti-proliferative activity
than (−)-solenopsin A in all three cell lines (Figure 2), sug-
gesting that the trans isomers are more potent than the
corresponding cis isomers. Elongation of the aliphatic side
chain with 8 carbons had a negative effect on potency, as
analogs S11 and S13 displayed a lower anti-proliferative
effect than both solenopsin and S12. Also, the only com-
pound that showed no anti-proliferative effect in any of
the cell lines was S11, which in addition to having the lon-
gest aliphatic side chain also has an extra methyl group on
the piperidine ring. Interestingly, analog S14, which has a
4 carbon longer aliphatic side chain than solenopsin,
turned out to be the most potent analog in human mel-
anoma A375 cells and murine angiosarcoma SVR cells
(Figure 2a and b). As S14 was significantly more potent
than S12 in all three cell lines, it would appear as if a
15-carbon side chain is the optimum length for anti-
proliferative activity. S15, which has the same length side
chain as solenopsin but lacks the methyl group and has an
extra hydroxyl group, also displayed potent anti-
proliferative effect in all three cell lines and in human
melanoma A2058 cells it was the most potent analog.
The effect of ceramide, solenopsin A, and analogs
S11-S15 was also assessed on two normal cutaneous cell
lines, namely primary melanocytes and primary keratino-
cytes (Additional file 1: Figure S1). In addition, the activity
of the compounds was assessed in HaCaTs, which are
immortalized hyperproliferative human keratinocytes
(Additional file 1: Figure S1). The analogs S11 and S13,
which were inactive in the tumor cell lines, did not
have any activity in these cell lines either. Ceramide
only showed activity in primary melanocytes and keratino-
cytes (Additional file 1: Figure S1), but not in malignant
A375s, A2058s, and SVRs, (Figure 2). Interestingly, HaCat
cells, which represent premalignant keratinocytes, are
resistant to ceramide, supporting our hypothesis that lossof response to ceramide may represent an early event in
skin carcinogenesis. Solenopsin A and the analogs S12,
S14, and S15 had significant activity in all cell lines, in-
cluding malignant and primary cell lines (Figure 2 and
Additional file 1: Figure S1). Solenopsin A and active
analogs were shown to be non-toxic to reconstituted
skin equivalents (Additional file 1: Figure S2). Normal
keratinization was preserved as assessed by routine
histology (data not show).
Solenopsin inhibits functional Akt activity and PDK1
activation
Ceramides are found in the cell membrane where they
act as signaling molecules and play a role in a variety of
physiological conditions, such as: differentiation, prolifera-
tion, programmed cell death, apoptosis etc. [19]. The
underlying mechanisms are complex and the exact means
by which ceramides function as signaling molecules are
not clear. However, there are a number of studies that
show that ceramide inhibit the PI3K/Akt pathway [14]. To
determine whether solenopsin A and analogs have similar
modes of action as ceramide, we employed a FRET-based
Akt activity reporter (AktAR) and a PDK1 activation re-
porter targeted to membrane rafts (Lyn-PARE) [14,15].
The AktAR construct contains a binding domain (FHA1),
a substrate domain (FOXO), and two fluorescent proteins
that constitute a FRET pair. This reporter functions as
surrogate substrate for Akt and phosphorylation of the
substrate leads to a detectable change in FRET [15]. Lyn-
PARE contains the full-length PDK1 protein flanked by
two fluorescent proteins that constitute a FRET pair. This
construct also contains a motif derived from Lyn-kinase,
which targets it to membrane rafts. Activation of PDK1
leads to a conformational change and thereby a detectable
change in FRET [14]. Previously, these reporters have
been used to show that ceramide treatment inhibits
PDGF-induced Akt activity and activation of PDK1 in
membrane rafts [14]. At 20 μM concentrations both (+)-
and (−)-solenopsin A inhibited Akt activity (AktAR) and
PDK1 activation (Lyn-PARE) to similar extent as treat-
ment with 50 μM of ceramide (Figure 3). At 10 μM
concentrations some inhibition of Akt activity and
PDK1 activation could be seen for both (+)- and
(−)-solenopsin A. At 10 μM S13 and possibly also S12
displayed some inhibition of Akt activity and PDK1 ac-
tivation. No significant inhibition could be seen for any
of the other solenopsin analogs (Figure 3).
Translocation of PTEN to membrane rafts
To examine whether solenopsin recruits PTEN to
membrane rafts, as ceramide does, sucrose density gradi-
ent fractionation was performed followed by evalu-
ation of the PTEN levels in each fraction. PTEN
negatively regulates the PI3K/Akt signaling, which
Figure 2 Assessment of anti-proliferative activity for solenopsin and analogs S11-S15. The anti-proliferative effect of (+)-solenopsin A ((+) Sol. A),
(−)-solenopsin A ((−) Sol. A), ceramide C2, and solenopsin analogs S11-S15 were evaluated in (a) A375 cells, (b) SVR cells, and (c) A2058 cells.
50,000 cells/well were plated and treated for 24 h with each compound. The first DMSO bar in each chart serves as control for (+)-solenopsin A,
(−)-solenopsin A, and ceramide C2. The second DMSO bar is the control for S11-S15. The displayed data are an average of four experiments ± s.d.
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Figure 3 Solenopsin A inhibits Akt activity (AktAR) and PDK1
activation (Lyn-PARE). NIH3T3 cells were transfected with AktAR
or Lyn-PARE and serum starved for 24 h, followed by 1 h treatments
with DMSO, ceramide C2, (+)-solenopsin A ((+) Sol. A), (−)-solenopsin
A ((−) Sol. A) or solenopsin analogs S11-S15. To study Akt activity
and PDK1 activation, 50 ng/mL of PDGF was added followed by
immediate imaging. FRET ratio of regions of interest at cell cytosol and
at cell periphery representing the plasma membrane were used,
respectively. Akt activity is measured by AktAR response (dark
grey columns) and PDK1 activation by Lyn-PARE response (light
grey columns). All the ratios were normalized with the ratio before PDGF
addition. Data shown are an average of at least three experiments ± s.d.
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(phosphatidylinostol (3,4,5)-triphosphate) to PIP2 (phos-
phatidylinositol (4,5)-biphosphate). As most PTEN is
usually localized to nonraft regions [14,20,21], studies
suggest that ceramide inhibits PI3K/Akt signaling by
translocating PTEN from nonraft regions into lipid
rafts [15,22,23].
As expected, the amounts of PTEN seem to be
higher in lipid raft fractions from cells treated with
ceramide (fraction 1–4) (Additional file 1: Figure S3).
The compound that appeared to have the largest amount
of PTEN in the raft fractions was (−)-solenopsin A
(Additional file 1: Figure S3). (+)-solenopsin A and
S12-treated cells showed similar amounts of PTEN in
the raft fractions as the ceramide treated cells (Additional
file 1: Figure S3). The rest of the analogs (S13-S15) ap-
peared to have similar or even lower amounts of PTEN in
lipid rafts than the control (Additional file 1: Figure S3). It
is worth pointing out that for these experiments the use of
a loading control is not possible. Therefore, these results
should only be regarded as an indication of the com-
pounds ability to recruit PTEN to membrane rafts. How-
ever, the FRET-based analysis was largely consistent with
the PTEN localization as demonstrated by sucrose density
fractionation.Solenopsin A and analogs effect on signaling pathways is
context dependent
A375 (human melanoma), SVR (murine angiosarcoma),
and A2058 (human melanoma) cells treated with solenop-
sin A and analogs were evaluated by Western-blotting
with p-Akt S473, p-MAPK 44/42, and B-actin (Additional
file 1: Figure S4 and Additional file 1: Table S1). In A375
human melanoma cells, an up-regulation of p-Akt S473
and p-MAPK 44/42 could be seen for (+)- and (−)-sole-
nopsin A, as well as for analogs S12-S15. In SVR murine
angiosarcoma cells on the other hand, p-Akt S473 and p-
MAPK 44/42 were down-regulated in all treatment
groups, and especially in cells treated with analog S15.
The results for the human melanoma A2058 cells were
similar to A375 cells but not as pronounced, i.e. there is a
slight up-regulation of p-Akt S473 and p-MAPK 44/42 in
some of the treatment groups compared to the control.
Both human melanoma cell lines (A375 and A2058) have
intact p53 and loss of p16ink4a [24], whereas the murine
angiosarcoma cell line (SVR) has defective p53 function
due to the presence of SV40 large T antigen [11]. This
may account for the observed difference in cell signaling
between these cell lines.
Solenopsin A and analogs affect mitochondrial function
Although solenopsin A recruits PTEN to lipid rafts
(Additional file 1: Figure S3), it does not appear to
be enough to dephosphorylate Akt (Additional file 1:
Figure S4) in the human melanoma cell lines A375 and
A2058 (both are wild type p53) like it did in 786-O renal
cell carcinoma cells (mutant p53) [1]. One explanation
for the anti-proliferative activity of solenopsin and ana-
logs could be that they, like ceramide, also localize to
mitochondria and increase the production of reactive
oxygen [25], thereby causing mitophagy and cell death.
Cellular oxygen consumption rate (OCR) can be indicative
of mitochondrial function. To investigate if solenopsin A
and analogs alter mitochondrial function in human head
and neck squamous carcinoma cells like ceramide [8], UM-
SCC1A cells were treated with 10 μM of solenopsin and
analogs, followed by incubation for 24 hours. Cells treated
with (+)- and (−)-solenopsin A, S12, S14, and S15 dis-
played reduced OCR compared to control, while cells
treated with S13 have slightly reduced OCR and cells
treated with S11 show little change in OCR compared to
the control (Figure 4). To verify that mitophagy is the
reason for the observed decrease in OCR, a Cyto-ID Au-
tophagy Staining assay was used. The dye stains autopha-
gosomes and co-localizes with LC3-II. UM-SCC1A cells
were treated with DMSO (control) and 10 μM of (−)-sole-
nopsin A or analog S14 for 18 h. A significant increase in
fluorescence could be seen for (−)-solenopsin A compared
to the control, which verifies that (−)-solenopsin A in-
duces autophagy (Additional file 1: Figure S5). Analog
Figure 4 Solenopsin A and analogs reduce oxygen consumption rate. UM-SCC1A cells were plated 15,000/well and treated for 24 h with 10 μM
of (+)-solenopsin A ((+) Sol. A), (−)-solenopsin A ((−) Sol. A), and solenopsin analogs S11-S15. Oxygen consumption rate (OCR) was measured as
pmoles O2/minute using a Seahorse Biosciences instrument. Data shown are an average of three experiments ± s.d.
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agy; instead it looks as if S14 may even decrease basal
levels of autophagy (Additional file 1: Figure S5).
Solenopsin A and analogs elevate ROS levels
Ceramide is known to increase ROS production [25-27]
and given that Akt phosphorylation was elevated by
solenopsin and analog treatment in human melanoma
cells, and that elevated phosphorylation of Akt is a com-
mon response to superoxide, we examined levels of
superoxide. There was a marked increase in superoxide
levels, as measured by DHE fluorescence, in both A375
human melanoma and SVR murine angiosarcoma cells
treated with the compounds (+)- and (−)-solenopsin A,
S12, S14, and S15 ranging from 1.7-2.3 fold compared
to vehicle treated cells (Figure 5). Compounds S11, and
S13 had no effect on superoxide levels (Figure 5).
Discussion
Ceramides play a role in physiologic cell death, as they
are involved in removal of undesired cells, and thus limit
both inflammation and neoplasia [28,29]. Ceramides
have also been implicated in mediating cell death due to
chemotherapy and radiation, and inability to generate
ceramides is linked to resistance to these treatments
[7,28-30]. Thus, restoration of ceramide is a potential
anti-angiogenic and anti-inflammatory modality, but is
complicated by difficult synthesis, low stability and rapid
metabolism. Therefore, analogs that do not suffer from
these disadvantages could be therapeutically beneficial.
We noted the similarity of solenopsin to ceramide and
hypothesized that solenopsin and analogs might act as
ceramide-like agonists. We thus evaluated their ceramide-
like activity at both the lipid membrane and mitochondria.A major obstacle to the widespread use of solenopsin
is obtaining sufficient quantities for preclinical and
clinical studies. Extraction of solenopsin from ants is
not feasible, and therefore large scale synthesis is re-
quired. All current synthetic methods suffer from reli-
ance on expensive reagents and multiple steps [31-33]. In
this paper, we demonstrate that solenopsin analogs can
be synthesized by lithiation of inexpensive industrial
dimethylpyridines, followed by alkylation of the lithiated
pyridines with alkyl halides, which can be varied. Finally,
the alkylated pyridine is hydrogenated to give the sole-
nopsin analogs (Figure 1). Each of these steps is amen-
able to scale up for industrial production [32,34]. In a
previous study by our group we showed that solenop-
sin analogs with shorter aliphatic side chains lacked
anti-proliferative activity in murine angiosarcoma SVR
cells [1]. Here we demonstrate that solenopsin analogs
with 8 carbon longer side chains (S11 and S13) also
lack significant anti-proliferative activity in murine
SVR angiosarcoma and human melanoma (A375 and
A2058) cells. On the other hand, S14, which has a
4 carbon longer side chain, and S15, which has the
same length side-chain but contains a hydroxyl group
and lacks the methyl group, are equally as potent as
(−)-solenopsin A in all three cell lines. Thus, optimal
length of the aliphatic side chain appears to be associ-
ated with high anti-proliferative activity.
One of the modes of ceramide’s activity is downregula-
tion of Akt, a serine-threonine kinase that plays a central
role in protecting tumor cells from apoptosis [35,36].
Akt, which originally was discovered as a viral oncogene,
has transforming activity in multiple cell types. PTEN is
a tumor suppressor that inhibits Akt activation in lipid
rafts. We used A375 human melanoma cells, which
Figure 5 Solenopsin A and analogs increase superoxide levels. Investigation of solenopsin and analogs S11-S14 effect on superoxide levels in
(a) A375 cells, and (b) SVR cells. Cells were treated for 24 h with 10 μM of (+)-solenopsin A ((+) Sol. A), (−)-solenopsin A ((−) Sol. A), and
solenopsin analogs S11-S15. Cells were trypsined and incubated for 10 min in 10 μM dihydroethedium, followed by analysis with a FACScan flow
cytometer. Data shown are an average of three experiments ± s.d.
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nopsin A on PTEN localization. Indeed, solenopsin A
did appear to cause relocalization of PTEN to lipid rafts
(Additional file 1: Figure S3). FRET-based reporters were
used to show that solenopsin A inhibits Akt activity
(AktAR) and PDK1 activation (Lyn-PARE) in lipid rafts
to the same extent as ceramide in NIH3T3 murine em-
bryonic fibroblast cells (Figure 3). Unexpectedly, we
found that solenopsin A increases Akt phosphorylation
in cells with wild type p53 (A375 and A2058), while it
decreases Akt activation in cells with defective p53 func-
tion (SVR and 786-O) (Additional file 1: Figure S4), thus
demonstrating a context dependent effect on tumor cells
[1,38]. Taken together it appears as if relocalization of
PTEN to lipid rafts is insufficient to block Akt activa-
tion, at least in cells with wild type p53. In addition,
solenopsin A is highly effective in killing A375 human
melanoma cells, despite no reduction of Akt phosphoryl-
ation. This implies that solenopsin’s killing of tumor
cells with wild type PTEN may not depend exclusively
on Akt deactivation, but may involve additional events,
such as mitochondrial induced cell death. Indeed, inves-
tigation of solenopsin and analogs affect on OCR-levels
revealed a similar trend as the proliferation assays.Solenopsin A and the analogs S12, S14 and S15 all
markedly decreased the OCR levels (Figure 4) in UM-
SCC1A cells. Interestingly, autophagy staining showed
that (−)-solenopsin A (trans geometry) but not S14 (cis
geometry) induced mitophagy (Additional file 1: Figure
S5), indicating strict stereochemical requirements for in-
duction of mitophagy. Thus, the trans geometry is not
essential for anti-proliferative activity, although it ap-
pears to be required for ceramide-like mitophagy activ-
ity. Further, our study of superoxide levels displayed a
similar pattern as the proliferation and OCR assays, i.e.
solenopsin A, S12, S14 and S15 substantially increased
superoxide, whereas S11 and S13 showed no effect (Fig-
ure 5). Figure 6 is a suggested model, based on our re-
sults, which show the effect of ceramide and solenopsin
on cell function. The FDA requires all new topical and
transdermal products to be evaluated for skin irritation
and sensitization [39]. A 3D cell culture of human skin
keratinocytes has been evaluated by European Center for
the Validation of Alternative Methods as an alternative
to the rabbit draize test, to avoid animal usage [40]. In
our study, solenopsin and analogs S12, S14 were found
to be non-irritant (Additional file 1: Figure S2). Thus,
solenopsin and analogs have the potential for further
Figure 6 A model for the effect of Ceramide and Solenopsin on cell function. Ceramide (Cer.) and solenopsin (Sol.) derivatives inhibit the AKT
pathway by translocating PTEN from non-raft regions into the rafts. Ceramide and solenopsin also increase mitochondrial ROS production, reduce
oxygen consumption (OCR), and induces autophagosome formation.
Karlsson et al. Vascular Cell  (2015) 7:5 Page 9 of 11development for topical treatment of both tumors and in-
flammatory disorders that are deficient in ceramide.
Conclusions
In this work we show that the naturally occurring
(−)-solenopsin A exhibit ceramide-like biological activity
in human melanoma cell lines and could therefore be
useful in treating hyperproliferative skin disorders. First,
we demonstrate that native (−)-solenopsin A mimics ca-
nonical functions of ceramide on cells, namely inhibition
of Akt activity and PDK1 activation in lipid rafts as well as
induction of mitophagy (Figure 6). Differences in cis-trans
geometry and chain length abrogate these functions. Sec-
ond, the response to solenopsin differs in cells of various
genetic backgrounds, with no effect or elevation of Akt
phosphorylation in cells with wild type p53 (A375,
A2058), while decreasing Akt phosphorylation in cells
with defective p53 (SVR, 786-O). Solenopsin and analogs
are also effective in killing cells with elevated Akt phos-
phorylation, which is an adverse prognostic factor in most
cancers. Based upon the novel hypothesis that restoration
of ceramide-like signaling may be beneficial in the treat-
ment of neoplastic and hyperproliferative skin disorders,
our assessment of solenopsin and analogs on normal cuta-
neous cells and premalignant cells demonstrate the poten-
tial of solenopsin and analogs to treat hyperproliferative
disorders when compared to ceramide.Supporting data
The data set supporting the results of this article is in-
cluded within the article and its additional file: Supple-
mentary Material Solenopsin.
Additional file
Additional file 1: Supplementary Material Solenopsin.
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